Last reviewed · How we verify
GLP1-RA
GLP1-RA, marketed by MaryAnn Banerji, is a small molecule that interacts with a specific target in the body, currently holding an established position in its therapeutic segment. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of disclosed primary indication and revenue data, which may limit strategic planning and investor confidence.
At a glance
| Generic name | GLP1-RA |
|---|---|
| Also known as | liraglutide (Victoza), semaglutide (Ozempic), dulaglutide (Trulicity) |
| Sponsor | MaryAnn Banerji |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients (PHASE4)
- Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment (NA)
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- GLP-1 RA on Liver OMICS in MASLD
- Transformative Research in Diabetic Nephropathy 2.0
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP1-RA CI brief — competitive landscape report
- GLP1-RA updates RSS · CI watch RSS
- MaryAnn Banerji portfolio CI